At Jazz, our purpose is to innovate to transform the lives of patients and their families. There is no better example of this objective than our presence at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies.
The 17 new abstracts to be presented at the meeting showcase our rapidly expanding neuroscience pipeline and portfolio. While this number of data presentations clearly demonstrates our leadership and our commitment to expanding research in sleep medicine, I am more excited about the potential for those living with these debilitating conditions.
For decades, Jazz has prioritized the lives of those living with these disorders and been a pioneer in sleep medicine and therapies. Across narcolepsy and idiopathic hypersomnia (IH), we have prioritized developing new medicines to benefit people with limited or no treatment options.
We take pride in developing first-of-its-kind treatments for patients that set new standards of care. As a company, we push ourselves to think holistically about patients’ health, which is why we aspire to develop next-generation therapies that address the needs of other sleep disorders.
To address the low understanding of idiopathic hypersomnia, Jazz partnered with the Hypersomnia Foundation last year to launch I Have IH, a disease awareness campaign aimed at increasing knowledge of idiopathic hypersomnia and encouraging those who may be struggling with the sleep disorder to have effective discussions with their healthcare providers. As part of the campaign, Jazz and the Hypersomnia Foundation surveyed healthcare providers, people with idiopathic hypersomnia and those who care for them to measure each group’s perceptions and knowledge of idiopathic hypersomnia. As part of the next evolution of the campaign, Jazz is proud to present two posters at SLEEP 2022 with the results of these surveys. We are excited to share these findings with the exact doctors who can help change the perception, understanding and awareness of this debilitating condition.
We continue to be pioneers in sleep medicine, building on the momentum we have had in narcolepsy and idiopathic hypersomnia, reinforcing our passion for advancing research, elevating patient voices and addressing unmet needs through our transformational medicines. For more information on Jazz’s presence at SLEEP 2022, follow along on Jazz’s Twitter and LinkedIn channels.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.